12:00 AM
 | 
May 25, 2009
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sanvar vapreotide regulatory update

An FDA advisory committee voted unanimously that Debiopharm has not demonstrated that the potential benefits outweigh the potential risks of Sanvar vapreotide as an adjunctive therapy to endoscopic intervention for the control of acute esophageal bleeding as a result of portal...

Read the full 184 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >